Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA
Abstract Triple-negative breast cancer (TNBC) does not respond to HER2-targeted and hormone-based medicines. Epidermal growth factor receptor 1 (EGFR1) is commonly overexpressed in up to 70% of TNBC cases, so targeting cancer cells via this receptor could emerge as a favored modality for TNBC therap...
Main Authors: | Javad Parnian, Leila Ma’mani, Mohamad Reza Bakhtiari, Maliheh Safavi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-21601-w |
Similar Items
-
High-Capacity Mesoporous Silica Nanocarriers of siRNA for Applications in Retinal Delivery
by: Amelia Ultimo, et al.
Published: (2023-02-01) -
Nanocarriers for delivery of siRNA as gene silencing mediator
by: Aideé Morales-Becerril, et al.
Published: (2022-08-01) -
Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery
by: Ma, Xing, et al.
Published: (2014) -
Carbohydrate-based nanocarriers for targeted drug and siRNA delivery
by: Tan, Yu Jia
Published: (2016) -
Recent Advances in Mesoporous Silica Nanoparticles Delivering siRNA for Cancer Treatment
by: Xiaowei Xie, et al.
Published: (2023-10-01)